At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 15, 2026 at 08:45 ET
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective response rate and over 80% two-year survival rate, compared to 35% and ~35% respectively in a parallel trial without PDS01ADC. These results suggest a potentially significant clinical improvement for the company's cancer therapy platform.
- PDS01ADC trial showed 78% objective response rate vs 35% in control arm
- Two-year survival rate exceeded 80% with PDS01ADC vs ~35% without
- Data appears to demonstrate strong efficacy signal for PDSB's ADC platform
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access